Funding
Series B · Biotech

EpiBiologics raises $107m Series B for targeted protein degradation

GV, Johnson & Johnson Innovation–JJDC and Novartis Venture Fund joined the financing.

Updated Oct 16, 2026By RoundOS Funding desk

EpiBiologics raised $107 million in Series B financing on January 8. Participants included GV, Johnson & Johnson Innovation–JJDC, Novartis Venture Fund, Aulis Capital, Avego BioScience Capital, Samsara BioCapital, Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital and Mission BioCapital.

The company develops bispecific antibodies designed to degrade extracellular proteins.

Funding history

Series B · This round$107M

Sources

  1. EpiBiologicsprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related